ERBB2 and lung cancer: Additionally, preclinical studies have shown increased efficiency of oncolytic HSV expressing single-chain fragment (scFv) antibodies against human epidermal growth factor receptor 2 (HER2) in redirection against HER2+ lung cancer cells [7].